title: Genetic Variants in ASCT2 Gene are Associated with the Prognosis of Transarterial Chemoembolisation-Treated Early- Stage Hepatocelluar Carcinoma.
abstract: BACKGROUND
  Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. Transarterial chemoembolisation (TACE) is the standardized therapy for intermediate stage HCC. However, the prognosis for HCC patients treated by TACE greatly varies. Thus, there is a critical need for finding biomarkers to predict the prognosis of HCC patients. The amino acid transporter-2 (ASCT2) is involved in tumorigenesis and progression of many malignancies. This study aimed to evaluate the predictive role of two single nuclear polymorphisms (SNPs, rs3826793 and rs2070246) in the ASCT2 gene in HCC patients treated by TACE.
  
  
  METHODS
  Two functional SNPs (rs3826793 and rs2070246) in the ASCT2 gene were selected and genotyped using the Sequenom iPLEX genotyping system in a cohort of 448 unresectable Chinese HCC patients treated by TACE. Univariate and multivariate Cox proportional hazards models and Kaplan-Meier curves were used for the prognosis analyses.
  
  
  RESULTS
  There was no significant association between two SNPs (rs3826793 and rs2070246) in the ASCT2 gene and overall survival of TACE treated HCC patients. However, we demonstrated that patients with early stage HCC carrying T genotype in rs2070246 showed better OS than those carrying CC genotype (P=0.023).
  
  
  CONCLUSIONS
  We demonstrated that patients with early stage HCC carrying T genotype in rs2070246 showed better OS than those carrying CC genotype.
authors.affiliation: Department of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China E-mail : yangyefa55@163.com.
authors.forename: Nai-Jian
authors.initials: NJ
authors.lastname: Ge
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Shi
authors.forename: Xiao-He
authors.initials: XH
authors.lastname: Yu
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
authors.forename: You-Sheng
authors.initials: YS
authors.lastname: Wu
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Chen
authors.forename: Jin
authors.initials: J
authors.lastname: Zhang
authors.forename: Ye-Fa
authors.initials: YF
authors.lastname: Yang
mesh_terms: D026962:Amino Acid Transport System ASC / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D016022:Case-Control Studies; D016461:Chemoembolization, Therapeutic / Q000401:mortality*; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008113:Liver Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015778:Minor Histocompatibility Antigens; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D026962:Amino Acid Transport System ASC; D014408:Biomarkers, Tumor; D015778:Minor Histocompatibility Antigens; C420506:SLC1A5 protein, human